Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

Status:	Completed
Conditions:	Neurology, Neurology
Therapuetic Areas:	Neurology
Healthy:	No
Age Range:	18 - 70
Updated:	8/11/2016
Start Date:	April 2011
End Date:	October 2015

A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

The primary objective of this study is to evaluate the long-term safety and tolerability of
peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301
(NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this
study is to describe long-term multiple sclerosis (MS) outcomes in participants originally
treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.

Key Inclusion Criteria:

- Must have completed the study treatment and visit schedule through Week 96 in Study
105MS301 (NCT00906399).

Key Exclusion Criteria:

- Subjects exceeding more than 6 weeks since completion of the Week 96 visit of Study
105MS301 (NCT00906399).

- Subjects with any clinically significant lab abnormalities, malignancies, cardiac,
endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
neurologic, dermatologic, psychiatric, renal, or other major disease

- Pregnant or nursing women.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

We found this trial at

sites

Clinical Trial Facility in Sint-Truiden

Sint-Truiden,

from

Sint-Truiden,